Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy
Clinical trial NCT05585580 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05585580
- Sponsor
- Qilu Hospital of Shandong University
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-01
- Primary completion
- 2026-04-30
- Enrollment
- 59
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.